Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Exp Ther ; 350(1): 69-78, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24891526

ABSTRACT

The opioid and cannabinoid systems play a crucial role in multiple physiological processes in the central nervous system and in the periphery. Selective opioid as well as cannabinoid (CB) receptor agonists exert a potent inhibitory action on gastrointestinal (GI) motility and pain. In this study, we examined (in vitro and in vivo) whether PR-38 (2-O-cinnamoylsalvinorin B), a novel analog of salvinorin A, can interact with both systems and demonstrate therapeutic effects. We used mouse models of hypermotility, diarrhea, and abdominal pain. We also assessed the influence of PR-38 on the central nervous system by measurement of motoric parameters and exploratory behaviors in mice. Subsequently, we investigated the pharmacokinetics of PR-38 in mouse blood samples after intraperitoneal and oral administration. PR-38 significantly inhibited mouse colonic motility in vitro and in vivo. Administration of PR-38 significantly prolonged the whole GI transit time, and this effect was mediated by µ- and κ-opioid receptors and the CB1 receptor. PR-38 reversed hypermotility and reduced pain in mouse models mimicking functional GI disorders. These data expand our understanding of the interactions between opioid and cannabinoid systems and their functions in the GI tract. We also provide a novel framework for the development of future potential treatments of functional GI disorders.


Subject(s)
Abdominal Pain/drug therapy , Cannabinoid Receptor Agonists/pharmacology , Diterpenes, Clerodane/therapeutic use , Gastrointestinal Motility/drug effects , Irritable Bowel Syndrome/drug therapy , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, mu/agonists , Abdominal Pain/complications , Administration, Oral , Animals , Cannabinoid Receptor Antagonists/pharmacology , Diarrhea/complications , Diarrhea/drug therapy , Disease Models, Animal , Diterpenes, Clerodane/administration & dosage , Diterpenes, Clerodane/chemistry , Diterpenes, Clerodane/pharmacology , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Injections, Intraperitoneal , Irritable Bowel Syndrome/complications , Male , Mice , Motor Activity/drug effects , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Receptors, Opioid, mu/antagonists & inhibitors
2.
J Appl Microbiol ; 116(2): 269-87, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24238211

ABSTRACT

AIMS: This article describes the qualitative and quantitative analyses of untypical compounds in the cuticular and internal lipids of four dipteran species. For isolated compounds, antimicrobial activity against 18 reference strains of bacteria and fungi was determined. METHODS AND RESULTS: In this study, gas chromatography (GC) combined with mass spectrometry (GC-MS) was used to analyse the surface and internal compounds of four fly species. Seven untypical compounds from both pre-imaginal and imaginal stages of examined insects were identified. Azelaic acid (AA) was the most abundant, while phenylacetic and phenylpropionic acids occurred in lower concentration. Minor quantities of sebacic acid, 2-methyl-2-hydroxybutanoic acid, tocopherol acetate and trace amounts of 2,4-decadienal were also detected. Tocopherol acetate was found only in cuticular lipids of Musca domestica larvae. Each compound was tested against several species of fungi and bacteria by determining minimal inhibitory concentration (MIC). Human pathogenic fungi were also investigated. Phenylpropionic acid showed the greatest antifungal activity. Bacterial strains were insensitive to the presence of identified compounds, apart from 2,4-decadienal which strongly inhibited bacterial growth. CONCLUSIONS: This is the first time that the chemical composition and the antimicrobial activity of untypical compounds in the cuticular and internal lipids of four fly species has been analysed. SIGNIFICANCE AND IMPACT OF THE STUDY: Determination of untypical compounds and their antimicrobial activity can effectively contribute to the knowledge concerning insect defence mechanisms.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antifungal Agents/pharmacology , Diptera/chemistry , Lipids/pharmacology , Aldehydes/chemistry , Aldehydes/pharmacology , Animals , Anti-Bacterial Agents/chemistry , Antifungal Agents/chemistry , Bacteria/drug effects , Decanoic Acids/chemistry , Decanoic Acids/pharmacology , Dicarboxylic Acids/chemistry , Dicarboxylic Acids/pharmacology , Female , Fungi/drug effects , Gas Chromatography-Mass Spectrometry , Humans , Hydroxybutyrates/chemistry , Hydroxybutyrates/pharmacology , Larva/chemistry , Lipids/chemistry , Male , Mass Spectrometry , Microbial Sensitivity Tests , Phenylacetates/chemistry , Phenylacetates/pharmacology , Propionates/chemistry , Propionates/pharmacology , alpha-Tocopherol/chemistry , alpha-Tocopherol/pharmacology
3.
Peptides ; 32(1): 99-103, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21055432

ABSTRACT

Candida albicans is known to be the organism most often associated with serious fungal infection, but other Candida spp. are emerging as clinical pathogens associated with opportunistic infections. Among antimycotic treatments, increasing attention is currently given to anti-infective drugs based upon naturally occurring peptides, such as the short lipopeptide palmitoyl PAL-Lys-Lys-NH2 (PAL). The aim of this study is to evaluate the activity of this peptide compared to the traditional antifungal agents Fluconazole (FLU), amphotericin B (AMB) and caspofungin (CAS) on Candida spp. 24 clinical isolates of Candida spp. were tested against PAL, FLU, AMB and CAS using in vitro susceptibility tests, time killing and checkerboard assay. All of the drugs studied showed good activity against clinical isolates of candida; in particular CAS and AMB which have MICs value lower than PAL and FLU. Moreover we observed synergistic interactions for PAL/FLU (81.25%), PAL/AMB (75%) and particularly for PAL/CAS (87.5). We think that our results are interesting since synergy between PAL and CAS might be useful in clinic trails to treat invasive fungal infections.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Lipoproteins/pharmacology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Candida/classification , Caspofungin , Echinocandins/therapeutic use , Fluconazole/therapeutic use , Lipopeptides , Microbial Sensitivity Tests
4.
Peptides ; 30(10): 1794-7, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19591887

ABSTRACT

Aim of our study was to investigate the in vitro effects of Tachyplesin III (TP), a potent disulfide-linked peptide, in dermatophytes infections, with respect to or in combination with terbinafine (TERB), against 20 clinical isolates of dermatophytes belonging to four species. A broth microdilution method following the CLSI recommendations (M38-A) was used for testing drugs alone and in combination. TERB MICs were significantly lower than those observed for TP (p<0.001). Testing for antifungal agents in combination was performed for TERB with TP for all the 20 isolates. TERB activity in combination with TP showed indifferent activity for 14 of the 20 isolates (70%); synergic activity for 6 of the 20 isolates (30%); no antagonistic activity was observed. Further experiments were conducted with Microsporum canis 133, Trichophyton rubrum 62 and Trichophyton mentagrophytes 91 for fungal biomass. TP and TERB did not show a significant growth reduction compared to the control against T. mentagrophytes and T. rubrum. A significant difference of growth reduction both for TP and TERB compared to controls was observed for M. canis (p<0.01). In conclusion our study demonstrated that Tachyplesin III has potential activity against dermatophytes. In addition, we observed that the in vitro activity of Tachyplesin III can be enhanced upon combination with terbinafine. Synergy could permit lower doses of the individual antifungal agents to be used more effectively and/or safely.


Subject(s)
Anti-Infective Agents/pharmacology , Antifungal Agents/pharmacology , Antimicrobial Cationic Peptides/pharmacology , Arthrodermataceae/drug effects , DNA-Binding Proteins/pharmacology , Naphthalenes/pharmacology , Peptides, Cyclic/pharmacology , Amino Acid Sequence , Anti-Infective Agents/therapeutic use , Antifungal Agents/therapeutic use , Antimicrobial Cationic Peptides/genetics , Antimicrobial Cationic Peptides/therapeutic use , DNA-Binding Proteins/genetics , DNA-Binding Proteins/therapeutic use , Dermatomycoses/drug therapy , Drug Synergism , Microbial Sensitivity Tests , Molecular Sequence Data , Naphthalenes/therapeutic use , Peptides, Cyclic/genetics , Peptides, Cyclic/therapeutic use , Terbinafine
5.
Br J Dermatol ; 161(2): 249-52, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19438437

ABSTRACT

BACKGROUND: An increasing number of antimycotics have become available for the treatment of dermatophytoses; however, there are reports suggesting recalcitrance to therapy or resistance of a dermatophyte against conventional treatment. Lipopeptides represent novel therapeutic drugs with a new mode of action. OBJECTIVES: The aim of this study was to investigate the in vitro effects of the lipopeptide Pal-Lys-Lys-NH(2) (PAL) alone and in combination with standard antifungal agents, such as fluconazole (FLU), itraconazole (ITRA) and terbinafine (TER) against 24 clinical isolates of dermatophytes belonging to four species. METHODS: A broth microdilution method following the Clinical and Laboratory Standards Institute recommendations (M38-A) was used for testing drugs alone and in combination. RESULTS: PAL minimum inhibitory concentrations (MICs) ranged from < or = 0.25 to > 16 microg mL(-1) and they were similar to those of FLU and higher than those of either ITRA or TER. Synergy, defined as a fractional inhibitory concentration (FIC) index of < or = 0.50, was observed in 67%, 52% and 15% of PAL/ITRA, PAL/TER and PAL/FLU interactions, respectively. None of these combinations yielded antagonistic interactions (FIC index > 4). When synergy was not achieved, there was still a decrease in the MIC of one or both drugs used in the combination. CONCLUSIONS: Our study demonstrates that PAL has potential activity against dermatophytes. In addition, the in vitro activity of PAL can be enhanced upon combination with standard drugs. This lipopeptide applied in the form of lacquer, spray or ointment, could represent an interesting new therapy, particularly when combined with conventional treatment in recalcitrant or resistant dermatophyte infections.


Subject(s)
Antifungal Agents/pharmacology , Arthrodermataceae/drug effects , Dermatomycoses/drug therapy , Lipoproteins/pharmacology , Drug Evaluation, Preclinical , Humans , Microbial Sensitivity Tests
6.
J Chemother ; 19(5): 514-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-18073150

ABSTRACT

The in vitro activity of the peptide IB-367, alone or combined with either fluconazole (FLU) or amphotericin B (AMB), was investigated against 25 Candida isolates belonging to five species. IB-367 minimum inhibitory concentrations (MICs) ranged from 2.0 to 32 microg/ml and it was active against both FLU-susceptible and - resistant isolates. A rapid fungicidal activity was observed. Synergism was documented in 41.6% and 44% of IB-367/FLU and IB-367/AMB interactions, respectively. Antagonism was never observed. The broad antifungal activity and the positive interactions with AMB and FLU suggest that IB-367 represents a promising candidate against infections due to Candida spp.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Peptides/pharmacology , Amphotericin B/administration & dosage , Antimicrobial Cationic Peptides , Candidiasis/drug therapy , Drug Resistance, Fungal , Drug Synergism , Drug Therapy, Combination , Fluconazole/administration & dosage , Humans , In Vitro Techniques , Microbial Sensitivity Tests
7.
Gut ; 52(6): 874-8, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12740345

ABSTRACT

BACKGROUND: Postoperative morbidity in patients with obstructive jaundice remains high because of increased susceptibility to endotoxin and the inflammatory cascade. AIMS: An experimental study was designed to investigate the efficacy of protegrin peptide IB-367, an antimicrobial positively charged peptide, in neutralising Escherichia coli 0111:B4 lipopolysaccharide (LPS) in bile duct ligated rats. METHODS: Adult male Wistar rats were injected intraperitoneally with 2 mg/kg E coli 0111:B4 LPS one week after sham operation or bile duct ligation (BDL). Six groups were studied: sham with placebo, sham with 120 mg/kg tazobactam-piperacillin (TZP), sham with 1 mg/kg IB-367, BDL with placebo, BDL with 120 mg/kg TZP, and BDL with 1 mg/kg IB-367. RESULTS: Main outcome measures were: endotoxin and tumour necrosis factor alpha (TNF-alpha) concentrations in plasma, evidence of bacterial translocation in blood and peritoneum, and lethality. After LPS, TNF-alpha plasma levels were significantly higher in BDL rats compared with sham operated animals. IB-367 caused a significant reduction in plasma endotoxin and TNF-alpha concentrations compared with placebo and TZP treated groups. In contrast, both TZP and IB-367 significantly reduced bacterial growth compared with saline treatment. Finally, LPS induced 60% and 55% lethality in BDL placebo and TZP treated rats and no lethality in sham operated rats, while only IB-367 significantly reduced lethality to 10%. CONCLUSIONS: By virtue of its dual antimicrobial and antiendotoxin properties, IB-367 could be an interesting compound to inhibit bacterial translocation and endotoxin release in obstructive jaundice.


Subject(s)
Cholestasis/surgery , Endotoxemia/prevention & control , Escherichia coli Infections/prevention & control , Postoperative Complications/prevention & control , Proteins/therapeutic use , Animals , Anti-Infective Agents/therapeutic use , Antimicrobial Cationic Peptides , Bacterial Translocation/drug effects , Bile Ducts/surgery , Disease Models, Animal , Ligation , Lipopolysaccharides/toxicity , Male , Peptides , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/metabolism
8.
Acta Microbiol Pol ; 49(3-4): 243-51, 2000.
Article in English | MEDLINE | ID: mdl-11293657

ABSTRACT

The susceptibility (MIC) of 44 strains of anaerobic bacteria isolated from the oral cavity and 3 standard strains to statherin and its C-terminal fragments with sequences QYQQYTF, YQQYTF, QQYTF, QYTF and YTF was determined by means of plate dilution technique in Brucella agar with 5% content of defibrinated sheep's blood, menadione and hemin. The culture was anaerobic. As shown, at concentrations from 12.5 to 100 microg/ml statherin and its C-terminal fragments inhibited the growth of anaerobic bacteria isolated from the oral cavity. Peptostreptococcus strains were the most susceptible to statherin and YTF (MIC < or = 12.5 mg/ml), whereas the most susceptible to the peptides investigated were Fusobacterium necrogenes and Fusobacterium necrophorum strains: QYQQYTF, YQQYTF, QQYTF, QYTF (MIC < or = 12.5 microg/ml). Prevotella oralis, Bacteroides forsythus and Bacteroides ureolyticus strains exhibited the lowest susceptibility (MIC > 100 microg/ml). When analysing the bacteriostatic activity of statherin it should be pointed out that the concentrations of this peptide used in microbiological investigations are within the range of physiological concentrations determined for whole saliva when at rest and stimulated in healthy donors of 19-25 years of age. Since the anaerobes investigated may be involved in the diseases of periodontum, the results presented seem to have also a practical aspect, i.e. a possibility to apply the C-terminal fragments of statherin as a novel therapeutic agent, affecting favourably the oral cavity.


Subject(s)
Bacteria, Anaerobic/drug effects , Gram-Negative Anaerobic Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Mouth/microbiology , Salivary Proteins and Peptides/pharmacology , Amino Acid Sequence , Gram-Negative Anaerobic Bacteria/growth & development , Humans , Microbial Sensitivity Tests , Molecular Sequence Data , Periodontal Diseases/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...